Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates

Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Taylor said during a BofA Global Research virtual conference.

MarketBeat • Aug 17, 2026

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

Zacks Investment Research • Aug 17, 2026

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

Seeking Alpha • Aug 11, 2026

Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments, but further commercial validation is pending. The internal pipeline, led by REC-4881 for FAP, potentially lags competitors (more data is required) and is unlikely to generate significant revenue before 2030.

Seeking Alpha • Aug 10, 2026

RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down

Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.

Zacks Investment Research • Aug 6, 2026

Recursion Pharmaceuticals Q2 Earnings Call Highlights

Recursion Pharmaceuticals NASDAQ: RXRX outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming expectations for an operating runway through early 2028.

MarketBeat • Aug 5, 2026

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for drug discovery REC-4881 (MEK1/2 inhibitor): Additional Phase 2 data in Familial Adenomatous Polyposis (FAP) to be presented at the Presidential Plenary session at leading hereditary GI annual meeting in November 2026 REC-7735 (PI3Kα H1047R inhibitor): IND cleared, Phase 1/2 trial start in 2H26; a >100× mutant-selective PI3Kα H1047R inhibitor designed to improve therapeutic index by enabling deep suppression of the most common activating PI3Kα mutation while sparing wild-type PI3Kα Reduced 2026 cash operating expense guidance to 100-fold selectivity for the H1047R mutant over wild type in order to drive high, sustained target inhibition while avoiding hyperinsulinemia-driven reactivation The differentiated development candidate was delivered in 10 months and 242 compounds from first novel hit through Recursion's AI-native design platform, demonstrating the Company's ability to rapidly translate platform insights into optimized clinical candidates With the IND cleared, the Phase 1/2 ZINNIA clinical study for patients with select PIK3CA H1047R-mutant solid tumors ​will be initiated in the second half of 2026 For the rest of the portfolio, programs continue to progress as planned. Additional expected upcoming milestones across Recursion's internal pipeline: REC-1245 (RBM39): Additional Phase 1 dose escalation data expected in 2H26 REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27 REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27 REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27 Agentic AI is compounding Recursion's advantage across Biology, Design, and ClinTech: Target Discovery Agent pairs frontier AI reasoning with Recursion's proprietary multimodal maps to surface novel drug targets, enabling scientists to mine and extract insights from proprietary maps in hours rather than weeks.

GlobeNewsWire • Aug 5, 2026

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.41 per share a year ago.

Zacks Investment Research • Aug 5, 2026

Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, UT, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: Bank of America 2026 SMID Cap Executive Insights Event — Tuesday, August 11, 2026 Morgan Stanley 24th Annual Global Healthcare Conference — Tuesday, September 15, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com .  About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company decoding biology to radically improve lives.

GlobeNewsWire • Aug 4, 2026